Nabriva Therapeutics PLC (NBRVF)

[realfast95]

Brett Jensen tweet

https://www.themaven.net/thebiotechnation/hot-analyst-reads/4-hot-analyst-reads-for-tuesday-may-22nd-wyJtMah9XUuusZet5ZRAKg/

Nabriva (NBRV), whose stock fell over 15% in trading Monday after some safety concerns around Phase 3 trial results using its compound lefamulin in patients with moderate community-acquired bacterial pneumonia; received some support from the analyst community yesterday. Cantor Fitzgerald ($16 price target), Needham ($18 price target) and H.C. Wainwright ($20 price target) all reiterated Buy ratings on the stock after trial data hit. Here is what Needham's analyst had to say around the results

"Nabriva announced results from the second of two Phase 3 trials in Community Pneumonia (CABP) earlier today. Both FDA and EMA non- inferiority primary endpoints were met against comparator moxifloxacin. Safety and tolerability profile appears consistent w/ prior clinical trial data, although we note a higher incidence of primarily mild GI adverse events. We do not believe GI profile is sufficiently concerning to impact physician willingness to prescribe. Mgmt guided for NDA submission 4Q18. Overall, we view the Phase 3 program outcome as favorable and expect the drug to be approved mid-2019. We believe the unmet need in CABP and the unique suitability of lefamulin for this indication is underappreciated by investors. Peak sales in the hospital is likely modest, but we believe lefamulin can be relevant in the large outpatient community setting.”